Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: Where are we and where should we go?

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 2, 2005, Pages 137-140

  Bellentani, Stefano ^a,b,c  

^a Centro Studi Fegato   (Italy)

^b AUSL Modena   (Italy)

^c Fondo Studi Fegato   (Italy)

Author keywords

Apoptosis; Bile acids; Glucocorticoid receptor; UDCA

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; GLYCYRRHIZIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; RETINOL; RIFAMPICIN; STRESS ACTIVATED PROTEIN KINASE; URSODEOXYCHOLIC ACID;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CELL PROTECTION; CELL SURVIVAL; CHO CELL; CHOLESTEROL STONE; CONTROLLED STUDY; DNA BINDING; DNA RESPONSIVE ELEMENT; DRUG MECHANISM; DRUG RECEPTOR BINDING; IMMUNOMODULATION; LIVER CELL; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROMOTER REGION; RAT; REVIEW; TRANSACTIVATION;

ANIMALS; APOPTOSIS; CELL SURVIVAL; HEPATOCYTES; HUMANS; IMMUNOLOGIC FACTORS; RATS; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; URSODEOXYCHOLIC ACID;

EID: 14844310240     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200502000-00001     Document Type: Review

References (30)

1. Shoda M. Über die Ursodesoxychol säure aus Bärengallen und ihre physiologische Wirkung. J Biochem 1927; 7:505-510.
2. Hagey LR, Crombic DL, Espinosa E, Carey MC, Igimi H, Hofmann AF. Ursodeoxycholic acid in the Ursidac: biliary bile acid of bears, pandas, and related carnivores. J Lipid Res 1993; 34:1911-1917.
3. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Dig Dis Sci 1982; 24:737-761.
4. Poupon R, Poupon RE. Ursodeoxycholic acid therapy of chronic cholestatic condition in adults and children. Pharmacol Ther 1995; 66:1-15.
5. Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow up. A pilot study. Dig Dis Sci 1985; 30:642-649.
6. Poupon R, Poupon RE, Calmus Y, Chretien Y, Ballet F, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1:834-836.
7. Bellentani S, Tabarroni G, Barchi T, Ferretti I, Fratti N, Villa E, Manenti F. Effect of ursodeoxycholic acid (UDCA) treatment on alanine-transferase (ALT) and gammaglutamyl-transpeptidase (GGT) serum levels in patients with hyper-transaminasemia: results from a double-blind controlled clinical trial. J Hepatol 1989; 8:7-12.
8. Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993; 19:459-464.
9. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884-890.
10. Eriksson LS, Olsson R, Glauman H, Prytz H, Befrits R, Ryden BO, et al. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. Scand J Gastroenterol 1997; 32:179-186.
11. Goulis J, Leandro G, Burroughs A. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354:1053-1060.
12. Mitchell SA, Bansi DS, Hunt N, von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121:900-907.
13. Palma J, Reyes H, Ribalta J, Hernandez I, Sandoval L, Almuna R, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997; 27:1022-1028.
14. Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 1996; 23:1484-1490.
15. Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997; 25:519-523.
16. Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:975-981.
17. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36:525-531.
18. Neuman MG, Cameron RG, Shear NH, Bellentani S, Tiribelli C. Effect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell line. Gastroenterology 1995; 109:555-563.
19. Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol 1994; 29(suppl 204):1-15.
20. Trauner M, Graziadei IW. Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver disease [Review]. Aliment Pharmacol Ther 1999; 13:979-995.
21. Schoemaker MH, Conde de la Rosa L, Buist-Homan M, Vrenken TE, Havinga R, Poelstra K, et al. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 2004; 39:1563-1573.
22. Backbinder L, Robinson RP. The glucocorticoid receptor: molecular mechanism and new therapeutic opportunities. Curr Drug Targets - Inflamm & Allergy 2002; 1:127-136.
23. Calleja C, Pascussi JM, Maurel P, Vilarem MJ. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nature Med 1998; 4:92-96.
24. Audouin-Chevallier I, Pallet V, Coustaut M, Alfos S, Higueret P, Gracin H. Retinoids modulate the binding capacity of the glucocorticoid receptors and its translocation from cytosol to nucleus in liver cells. J Steroid Mol Biol 1995; 52:321-328.
25. Nakashima YT, Sumida Y, Kakisaka Y, Nakajima Y, Ishikawa H, Sakamoto Y, et al. Effects of glycyrrhizin on glucocorticoid signaling pathway in hepatocytes. Dig Dis Sci 2002; 47:1775-1781.
26. Weitzel C, Stark D, Kullmann F, Scholmerich J, Holstege A, Falk W. Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes. Eur J Gastroenterol Hepatol 2005; 17:169-177.
27. Tanaka H, Makino I. Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor. Biochem Biophys Res Commun 1992; 188: 942-948.
28. Tanaka H, Makino Y, Miura T, Hirano F, Okamoto K, Komura K, et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J Immunol 1996; 156:1601-1608.
29. Takanori M, Ouchida R, Yoshikawa N, Okamoto K, Makino Y, Nakamura T, et al. Functional modulation of the glucocorticoid receptor and suppression of NF-κB-dependent transcription by ursodeoxycholic acid. J Biol Chem 2001; 276:47371-47378.
30. Jung D, Fantin AC, Scheure U, Fried M, Kullak-Ublick GA. Human ileal bile acid transporter gene ASBT (SLC1OA2) is transactivated by the glucocorticoid receptor. Gut 2004; 53:78-84.